<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10646877</article-id><article-id pub-id-type="pmc">2363271</article-id><article-id pub-id-type="pii">6690915</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.0915</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m<sup>&#x02212;2</sup> and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Watts</surname><given-names>M J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ings</surname><given-names>S J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leverett</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>MacMillan</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Devereux</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Goldstone</surname><given-names>A H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Linch</surname><given-names>D C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Haematology, University College London, 98 Chenies Mews, London, WC1E 6HX, UK</aff><aff id="aff2"><label>2</label>Department of Haematology, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK</aff><pub-date pub-type="epub"><day>18</day><month>01</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>01</month><year>2000</year></pub-date><volume>82</volume><issue>2</issue><fpage>278</fpage><lpage>282</lpage><history><date date-type="received"><day>03</day><month>03</month><year>1999</year></date><date date-type="rev-recd"><day>06</day><month>07</month><year>1999</year></date><date date-type="accepted"><day>02</day><month>08</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Cyclophosphamide 1.5 g m<sup>&#x02212;2</sup>followed by granulocyte colony-stimulating factor (G-CSF) is an effective peripheral blood stem cell (PBSC) mobilizing regimen, but has limited anti-lymphoma activity. We therefore assessed the mobilizing potential of ESHAP (etoposide, ara-C, methylprednisolone and cisplatin), a potent second-line lymphoma regimen followed by G-CSF. The results were compared in 78 patients with relapsed or resistant lymphomas with the use of cyclophosphamide 1.5 g m<sup>&#x02212;2</sup>followed by G-CSF in a matched pairs analysis, matching the ESHAP recipients (for predetermined prognostic factors) from a cohort of 178 lymphoma patients mobilized with cyclophosphamide and G-CSF. The total numbers of mononuclear cells collected at apheresis was similar with both regimens but ESHAP plus G-CSF resulted in a significantly higher percentage of CD34+ cells, absolute number of CD34+ cells and GM-CFC (all with <italic>P</italic> -values &#x0003c; 0.001). The number of patients requiring only one apheresis harvest to achieve a CD34+ cell yield of &#x0003e; 2.0 &#x000d7; 10<sup>6</sup>kg<sup>&#x02212;1</sup>was greatly increased in the ESHAP recipients (56/78 vs 17/78, <italic>P</italic>&#x0003c; 0.001). The total number of progenitor cells collected was not significantly different with the two mobilization regimens because of this higher number of apheresis in the cyclophosphamide group. The proportion of patients who failed to achieve a minimum CD34+ cell target of 1 &#x000d7; 10<sup>6</sup>kg<sup>&#x02212;1</sup>with the pooled harvests was less in the ESHAP arm (four patients vs nine patients) despite an increased number of aphereses in the cyclophosphamide recipients. ESHAP plus G-CSF is well tolerated and is an excellent mobilization regimen in patients with pre treated lymphoma.  &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>lymphoma</kwd><kwd>PBSC</kwd><kwd>ESHAP</kwd><kwd>cyclophosphamide</kwd><kwd>mobilization</kwd></kwd-group></article-meta></front></article>


